Indaptus Therapeutics
INDP
6 hedge funds and large institutions have $129K invested in Indaptus Therapeutics in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
50% more funds holding
Funds holding: 4 → 6 (+2)
37% more capital invested
Capital invested by funds: $93.7K → $129K (+$34.9K)
1.31% more ownership
Funds ownership: 1.84% → 3.15% (+1.3%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$83.7K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$57.9K |
| 3 |
Morgan Stanley
New York
|
+$5.78K |
| 4 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$84.4K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.7K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$73 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $71K | +$83.7K | +39,018 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $49.2K | +$57.9K | +27,007 | New |
|
|
3
Morgan Stanley
New York
| $4.91K | +$5.78K | +2,697 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $3.44K | -$2.7K | -1,261 | -40% |
|
|
SS
5
SBI Securities
Tokyo,
Japan
| $31 | – | – | – |
|
|
6
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $4 | +$4 | +2 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| – | -$84.4K | -29,002 | Closed |
|
|
8
Bank of America
Charlotte,
North Carolina
| – | -$73 | -25 | Closed |
|
INDP Hedge Fund Activity: Q1 2026 in Review
6 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q1 2026, worth a combined $129K — up 37% from $93.7K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new INDP positions and 2 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $83.7K. The largest seller was UBS Group, exiting entirely with an estimated $84.4K sold.
- 6 institutional investors held Indaptus Therapeutics (INDP) as of Q1 2026, up from 4 in Q4 2025.
- Funds reported $129K of Indaptus Therapeutics stock for Q1 2026, up 37% quarter-over-quarter.
- 4 funds opened new Indaptus Therapeutics positions in Q1 2026 and 2 closed out, a net change of +2 holders.
- The largest Indaptus Therapeutics buyer in Q1 2026 was Citadel Advisors, an estimated $83.7K added.
- The largest Indaptus Therapeutics seller in Q1 2026 was UBS Group, an estimated $84.4K sold.
Based on aggregated 13F filings for Q1 2026.